Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.

Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK.

Mol Cancer Ther. 2014 Apr;13(4):890-901. doi: 10.1158/1535-7163.MCT-13-0870. Epub 2014 Feb 12.

2.

Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity.

Li H, Ponder EL, Verdoes M, Asbjornsdottir KH, Deu E, Edgington LE, Lee JT, Kirk CJ, Demo SD, Williamson KC, Bogyo M.

Chem Biol. 2012 Dec 21;19(12):1535-45. doi: 10.1016/j.chembiol.2012.09.019. Epub 2012 Nov 8.

3.

A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.

Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M.

Nat Med. 2009 Jul;15(7):781-7. doi: 10.1038/nm.1978. Epub 2009 Jun 14. Erratum in: Nat Med. 2009 Nov;15(11):1333.

PMID:
19525961
4.

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J.

J Med Chem. 2009 May 14;52(9):3028-38. doi: 10.1021/jm801329v.

PMID:
19348473
5.

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK.

Cancer Res. 2007 Jul 1;67(13):6383-91.

6.

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ.

Blood. 2007 Nov 1;110(9):3281-90. Epub 2007 Jun 25.

7.

Stable, stoichiometric delivery of diverse protein functions.

Lorens JB, Pearsall DM, Swift SE, Peelle B, Armstrong R, Demo SD, Ferrick DA, Hitoshi Y, Payan DG, Anderson D.

J Biochem Biophys Methods. 2004 Feb 27;58(2):101-10.

PMID:
14980783
8.

Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.

Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, Issakani SD, Molineaux S, Demo SD.

Drug Resist Updat. 2002 Dec;5(6):249-58. Review.

PMID:
12531181
9.

Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay.

Demo SD, Masuda E, Rossi AB, Throndset BT, Gerard AL, Chan EH, Armstrong RJ, Fox BP, Lorens JB, Payan DG, Scheller RH, Fisher JM.

Cytometry. 1999 Aug 1;36(4):340-8.

PMID:
10404150
10.

A novel splice variant of the cell death-promoting protein BAX.

Zhou M, Demo SD, McClure TN, Crea R, Bitler CM.

J Biol Chem. 1998 May 8;273(19):11930-6.

11.

ralGDS family members interact with the effector loop of ras p21.

Kikuchi A, Demo SD, Ye ZH, Chen YW, Williams LT.

Mol Cell Biol. 1994 Nov;14(11):7483-91.

12.

Signaling molecules that mediate the actions of FGF.

Demo SD, Kikuchi A, Peters KG, MacNicol AM, Muslin AJ, Williams LT.

Princess Takamatsu Symp. 1994;24:243-9. Review.

PMID:
8983079
13.
14.
15.
16.

Acute reduction of dopamine levels alters responses of basal ganglia neurons to selective D-1 and D-2 dopamine receptor stimulation.

Carlson JH, Bergstrom DA, Demo SD, Walters JR.

Eur J Pharmacol. 1988 Aug 2;152(3):289-300.

PMID:
2906003

Supplemental Content

Support Center